Why Immunovant, Inc. (IMVT) stock moved
Immunovant, Inc. (IMVT) shares tumbled 7.4% to $34.54 as of September 23, 2026, a significant decline from the prior close of $37.29. BestStocks flagged the session as a major change for IMVT. Below, we break down what changed for IMVT, why it matters for investors, how the stock reacted, and the catalysts on the calendar.
IMVT fell 7.4% to $34.54
Immunovant, Inc. moved -2.46% intraday from $37.29 to $36.37. Immunovant Inc. (IMVT) stock declined following the announcement that its proof-of-concept clinical trial for IMVT-1402 in cutaneous lupus erythematosus (CLE) did not reach statistical significance on the primary endpoint. Consequently, the company is discontinuing the development program for this indication amid a competitive landscape. --- #### 🔎 Key Clinical & Financial Takeaways - The Trial Failure: The Phase 2a trial involving 57 patients missed its primary efficacy metric regarding the CLASI-A score at Week 12. - Data Context & Pipeline Shift: Despite favorable safety profiles and numerical trends beating placebo, the results fell short of internal thresholds. Immunovant is reallocating resources toward other indications like Graves' disease, rheumatoid arthritis, myasthenia gravis, and Sjögren's disease, leaving other timelines unaffected. - Market Impact: Majority stakeholder Roivant Sciences (ROIV) also experienced a stock decline in sympathy with the news. --- Let me know if you would like to examine analyst price target adjustments or review the company's current cash runway. Monitor for follow-through at the close.
What it means for Immunovant, Inc. investors
For Immunovant, Inc. investors, the recent signals add up to a bearish shift. On the constructive side: Immunovant, Inc. (IMVT) moved +3.34% from $38.96 to $40.26 on 2026-07-17. Weighing against that: Material negative event; Sharp 7.4% decline — elevated risk. Wall Street's consensus price target sits at $40.00, implying +15.8% upside from $34.54. BestStocks rates the overall signal quality medium (69/100). With earnings roughly 47 days out, the next report is the most likely near-term test of the move.
IMVT price reaction
IMVT last traded at $34.54, down $2.75 (-7.37%) from the previous close of $37.29. The session traded on 2.3× average volume (very high), so the move carried above-average conviction. Over the past month the stock has ranged between $34.54 and $43.89, and it currently sits about 0% of the way up that band.
Bullish and bearish analyst opinions on Immunovant, Inc. (IMVT)
The consensus analyst price target on Immunovant, Inc. (IMVT) is $40.00, 15.8% above the recent $34.54. Over the past 90 days analysts logged 0 upgrades, 2 maintains, and 0 downgrades. Here is how the bullish and bearish cases on IMVT line up.
The bullish case
- Wall Street's consensus price target of $40.00 implies +15.8% upside from $34.54.
- The Street's most bullish target is $40.00 (+15.8%).
- Immunovant, Inc. (IMVT) moved +3.34% from $38.96 to $40.26 on 2026-07-17.
The bearish case
- Material negative event.
- Sharp 7.4% decline — elevated risk.
- High volume 2.3x on decline — distribution signal.
Weighing both sides, BestStocks' composite read of recent signals is bearish, as the bull-versus-bear meter above shows. This is an educational summary of the bull and bear case, not investment advice.
Analyst price targets and ratings are FMP consensus figures as of Sep 23, 2026; other aggregators may differ. High and low targets show the range of estimates, not forecasts.
Previous notable changes for IMVT
Frequently asked questions about IMVT
Why did Immunovant, Inc. (IMVT) stock move?
IMVT tumbled 7.4% to $34.54. The move coincided with the context summarized above, though no single company-specific catalyst was independently confirmed.
How much did IMVT stock fall?
IMVT lost 7.37% ($2.75) versus the prior close of $37.29, last trading at $34.54 on 2.3× average volume.
When is Immunovant, Inc.'s next earnings date?
IMVT's next earnings report is estimated for 2026-11-09 — about 47 days away.
What is the analyst price target for IMVT?
The consensus analyst price target for IMVT is $40.00, about 15.8% above the current $34.54. Over the past 90 days, analysts recorded 0 upgrades, 2 maintains, and 0 downgrades.
How BestStocks tracks IMVT
This page is generated automatically by BestStocks' change-detection system after its price and volume cleared IMVT-specific materiality thresholds, triggering an evidence check. It draws on 20 tracked change events for IMVT, cross-checked against the data sources listed below. Price, volume, and market-capitalization figures are the live intraday quote as of September 23, 2026 and refresh as new information is detected; for companies with multiple share classes, market-cap figures can differ by data source. Analyst price targets and ratings are FMP consensus. This is an educational summary of what changed and why — not personalized investment advice.